Dr Gary Baldwin, MD in Colville, WA - Obstetrics & Gynecology

Dr Gary Baldwin, MD is a Obstetrics & Gynecology physician based in Colville, Washington. Dr Gary Baldwin is licensed to practice in Maine (license number 016261) and his current practice location is 982 E Columbia Ave, Colville, Washington. He can be reached at his office (for appointments etc.) via phone at (509) 935-0824.

NPI number for Dr Gary Baldwin is 1265404776 and his current mailing address is 910 N Washington St, Ste 209, Spokane, Washington. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1265404776.

Contact Information

	Dr Gary Baldwin, MD
	982 E Columbia Ave, Colville, WA 99114-3316
	(509) 935-0824
	Not Available

Physician's Profile

Full Name	Dr Gary Baldwin
Gender	Male
Speciality	Obstetrics & Gynecology
Location	982 E Columbia Ave, Colville, Washington
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1265404776
Provider Enumeration Date: 02/07/2006
Last Update Date: 12/04/2007

Medical Identifiers

Medical identifiers for Dr Gary Baldwin such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1265404776	NPI	-	NPPES
AB32999	Other	WA	MEDICARE GROUP
8078300200	Other		ID MEDICAID
7469BA	Other	WA	ASURIS
8491862	Other	WA	WA MEDICAID

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207V00000X	Obstetrics & Gynecology	016261 (Maine)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Gary Baldwin is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Gary Baldwin, MD 910 N Washington St, Ste 209, Spokane, WA 99201-2202 Ph: (509) 232-1145	Dr Gary Baldwin, MD 982 E Columbia Ave, Colville, WA 99114-3316 Ph: (509) 935-0824

News Archive

Increasing exposure to either natural or artificial ultraviolet (UV) light should not be recommended as a supplemental source of vitamin D

Based on data reviewed by a consensus conference convened by the American Academy of Dermatology Association to examine the relationship between sunlight, tanning booths and vitamin D, renowned medical experts agreed that increasing exposure to either natural or artificial ultraviolet (UV) light should not be recommended as a supplemental source of vitamin D.

LSU Health New Orleans professor awarded $1.8 million grant to target intra-abdominal infections

Mairi Noverr, PhD, Associate Professor of Prosthodontics at LSU Health New Orleans School of Dentistry's Center of Excellence in Oral Biology, has been awarded a $1.8 million grant by the National Institute of Allergy and Infectious Diseases.

Children's friendships matter in the scramble for secondary schools

Now is the time that many parents will be choosing secondary schools for their children but with education policy mostly focused on individual success and achievement, the importance of children's school friendships is largely ignored, according to a study funded by the Economic and Social Research Council (ESRC).

Diagnostic guidelines for arthritis-related back pain result in excessive tests, delay in pain relief: Research

Slavishly following long-held guidelines for diagnosing the cause of arthritis-related back pain is resulting in excessive tests, delays in pain relief and wasteful spending of as much as $10,000 per patient, new Johns Hopkins-led research suggests.

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

Dr Gary Baldwin, MD - Obstetrics & Gynecology in Colville, WA